Interventional device developer Boston Scientific of Natick, MA, has completed enrollment in the first phase of its drug-eluting stent registry. The registry will collect and analyze clinical outcomes data for the Taxus Liberté paclitaxel- eluting stent system in the treatment of coronary artery disease.
Five hundred patients have been enrolled in the trial, which will eventually include more than 30,000 patients at centers in the U.S., Europe, and other international locations, according to Boston Scientific.
By AuntMinnie.com staff writers
June 21, 2005
Related Reading
Boston Scientific notches 400th Liberté enrollment, May 26, 2005
Boston Scientific posts strong Q1, April 20, 2005
Boston Scientific purchases CryoVascular Systems, April 19, 2005
Boston Scientific buys TriVascular, April 18, 2005
Boston Scientific gets FDA approval for Liberté stent, April 14, 2005
Copyright © 2005 AuntMinnie.com
